Short answer
Perspective Therapeutics, Inc. (CATX) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$32M
- −24.9% YoY · −21.1% QoQ
- EPS (diluted)
- −$0.27
- +22.9% YoY · −22.7% QoQ
Source: XBRL data from the Perspective Therapeutics, Inc. (CATX) Q3 2026 10-Q on SEC EDGAR. USD.
Perspective Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Grant revenue $0.2 million lower YoY; operating loss $34.3 million vs $27.9 million
- R&D expenses $26.1 million, up $5.8 million YoY, driven by clinical and manufacturing investment
- VMT-α-NET strongest program: Cohort 3 disease control 95%, versus Cohort 2 at 89%
- Cash, equivalents and short-term investments $201.7 million; operating cash use $83.5 million through nine months
- Expenses expected to rise; funding sufficient into 2028, with additional capital likely required before profitability
Risk Factors
- No material changes to 2025 Form 10-K risk factors
- Carried-forward risk: unidentified or presently unknown risks could materially adversely affect business
- Market risk: securities price could decline significantly or permanently
- General business risk: identified risks could materially adversely affect financial condition and results of operations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Perspective Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.